# Ben Creelan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ben-creelan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,962 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 32 |
| i10-index | 60 |
| Last Known Institution | Moffitt Cancer Center |
| OpenAlex ID | https://openalex.org/A5064826649 |
| ORCID iD | 0000-0002-2728-8070 |
| Works | 187 |

## Researcher papers

- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/genomic-features-of-response-to-combination-immunotherapy-in-patients-with/)
- [Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma](https://scholariq.org/papers/differential-association-of-stk11-and-tp53-with-kras-mutation-associated-gene/)
- [Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial](https://scholariq.org/papers/tumor-infiltrating-lymphocyte-treatment-for-anti-pd-1-resistant-metastatic-lung/)
- [Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153](https://scholariq.org/papers/continuous-versus-1-year-fixed-duration-nivolumab-in-previously-treated-advanced/)
- [Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)](https://scholariq.org/papers/safety-efficacy-and-patient-reported-health-related-quality-of-life-and-symptom/)
- [Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells](https://scholariq.org/papers/sirt2-inhibition-enhances-metabolic-fitness-and-effector-functions-of-tumor/)
- [Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer](https://scholariq.org/papers/phase-i-ib-study-of-pembrolizumab-plus-vorinostat-in-advanced-metastatic-non/)
- [Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors](https://scholariq.org/papers/receptor-tyrosine-kinase-fusions-and-braf-kinase-fusions-are-rare-but-actionable/)
- [Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases](https://scholariq.org/papers/outcomes-targeting-the-pd-1-pd-l1-axis-in-conjunction-with-stereotactic/)
- [Real World Safety of Tarlatamab Step-Up Dosing in Extensive Stage Small Cell Lung Cancer](https://scholariq.org/papers/real-world-safety-of-tarlatamab-step-up-dosing-in-extensive-stage-small-cell/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Moffitt Cancer Center](https://scholariq.org/institutions/moffitt-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.